StemCells Inc. (Nasdaq: STEM) is a clinical-stage biotechnology company focused on the development and commercialization of cell-based therapeutics to treat diseases of the central nervous system and liver. Though controversial to many people, cell-based discoveries are important in medical and scientific advances.

The company’s HuCNS-SC product candidate (purified human neutral stem cells) is undergoing clinical trials to treat retinal and spinal cord damage and will soon be showcased to neuroscientists around the globe. StemCells today announced it will present the results of its retinal degeneration and spinal cord injury research program at the Society for Neuroscience Annual Meeting later this month in Washington, D.C.

As the world’s largest organization centered on advances in understanding the brain and nervous system, The Society for Neuroscience has established this annual meeting to allow neuroscientists all around the world to present, observe and discuss scientific breakthroughs, technology and advances. StemCells has established an ongoing

...

Amarin Corporation (NASDAQ: AMRN) is a neuroscience company focused on the research, development and commercialization of novel drugs that address unmet patient needs. Amarin is committed to improving the lives of patients suffering from central nervous system and cardiovascular diseases.

Amarin continues to focus their efforts on employing a novel, proprietary platform based on knowledge of the chemical nature and highly vascular environment of the brain to develop pharmaceuticals in the area of neurology. The company’s unique technology of lipophilic drugs is predominately fat-soluble, which helps facilitate transportation across the blood-brain barrier. This is a crucial component since the majority of drugs that are currently available to treat neurological and psychiatric disorders have mechanisms of action targeting receptors of the brain or neurotransmitters located in the brain’s makeup.

The company has initiated a cardiovascular development program to capitalize on the known therapeutic benefits of

...

Investors turn to the large drug company stocks for several reasons. They are considered recession proof, they are a play on the ageing of the baby boomers, and they are often considered safer and less volatile than most other stocks. Since dividends are so vital to many investors they days, the high yielding big pharmas are of interest. All of the following have yields over 2.5%, PE's below 20, and PEGs below 3.Pfizer Inc. (PFE) Its drugs include Lipitor, Norvasc Caduet, Chantix/Champix, Lyrica, Geodon/Zeldox, Aricept, Zoloft, Celebrex, Vfend, Zyvox, Viagra, Detrol, and Zyrtec, and for animals; Clavamox/Synulox, RespiSureOne/StellamuneOne, Bovi-Shield Gold, Dectomax, and Draxxin. The stock yields 7.5% It has a PE of 12.7 and a PEG of 2.12 .Bristol Myers Squibb Co. (BMY) Its drugs include PLAVIX, AVAPRO/AVALIDE, PRAVACHOL, COUMADIN, REYATAZ, SUSTIVA, BARACLUDE, ERBITUX, TAXOL, SPRYCEL, IXEMPRA, ABILIFY, ORENCIA, and EFFERALGAN. The ...